[Immunotherapy and Alzheimer's disease].
Recent progress in biological studies on Alzheimer's disease (AD) could lead to a new strategy for its treatment. One of the representative and leading therapies is passive and active immunotherapy. The first active immunotherapy using the full length of Abeta protein was stopped due to the serious side-effect of encephalitis. Currently, a new revised immunotherapy using humanized mouse monoclonal antiserum against a part of Abeta protein is under clinical trials. Here, future advance concerning AD treatment as well as the present situation will be reviewed.
Arai
Heii
H
Department of Psychiatry, Juntendo University Faculty of Medicine, Tokyo, Japan. heii@juntendo.ac.jp
D000544:Alzheimer Disease / Q000209:etiology / Q000628:therapy*; D023582:Alzheimer Vaccines / Q000009:adverse effects; D016229:Amyloid beta-Peptides; D000818:Animals; D002795:Choline O-Acetyltransferase; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D015195:Drug Design; D006801:Humans; D007167:Immunotherapy
D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides; D002800:Cholinesterase Inhibitors; D002795:Choline O-Acetyltransferase